Drugs / rhThrombin
rhThrombin
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03611426 | Nov 2017 → Dec 2018 | — | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00245336 | Oct 2005 → Jun 2006 | — | ZymoGenetics | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rhThrombin | “The objective of this randomized, double-blind, comparative trial was to compare the efficacy, safety, and antigenicity of recombinant human thrombin (rhThrombin) and bovine...” PMID 17660072 ↗ Jun 2007 |
| Known as | recombinant human thrombin | “The objective of this randomized, double-blind, comparative trial was to compare the efficacy, safety, and antigenicity of recombinant human thrombin (rhThrombin) and bovine...” PMID 17660072 ↗ Jun 2007 |
| Known as | rThrombin | “Recombinant thrombin (rThrombin) is a potential hemostatic alternative to bovine and human plasma-derived thrombin.” PMID 18440754 ↗ Apr 2008 |
| Modality | Protein / enzyme biologic | “Recombinant thrombin (rThrombin) is a potential hemostatic alternative to bovine and human plasma-derived thrombin.” PMID 18440754 ↗ Apr 2008 |
| Route | Topical | “rhThrombin ( Topical )” NCT03611426 ↗ |